Trubion Pharma (TRBN) Announces Two Presentations of TRU-016 Product at 2009 ASH Meeting

FREE Breaking News Alerts from StreetInsider.com!

More News related to TRBN

Trubion Pharma (TRBN) Granted Early Termination of HSR Waiting Period Related to Puchase by Emergent (EBS)
Trubion Pharma (TRBN) Reports Q2 Loss of 28c, Beats by 6c; Guides FY10 Sales
Top 10 News Items 8/9-8/13: Fed Gives Green Light on QE; Cisco Shares Tumble as Earnings Disappoint; M&A Activity Strong This Week
Trading Radar for 08/13: Lowe's (LOW), Sysco Corp. (SYY), RINO Int'l (RINO), Valspar (VAL),
Unusual 11 Mid-Day Movers 08/13: UNCA, DYN, ALY, PRXI, TRBN, INTX Higher; TGAL, PSTB, TSTC, PDLI, DEG Lower

More News related to Corporate News

November 11, 2009 4:26 PM EST

Trubion Pharmaceuticals, Inc. (NASDAQ: TRBN) announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.

The presentations will include additional positive data from 1) an ongoing Phase 1 clinical trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), and 2) a preclinical study demonstrating the effect of Trubion's Tru-ADhanCe( technology in promoting enhanced natural killer cell mediated cytotoxicity against primary CLL cells. TRU-016 is Trubion's novel CD37-targeted therapy for the treatment of B-cell malignancies and is being developed in collaboration with Facet Biotech Corporation.

Presentation 3424: A Phase 1 Trial of TRU-016, An Anti-CD37 Small Modular Immunopharmaceutical (SMIP(TM)) Protein in Relapsed and Refractory CLL: Early Promising Clinical Activity

Monday, Dec. 7, 2009, 6:00 PM-8:00 PM
Hall E (Ernest N. Morial Convention Center)
Poster Board III-361

Conclusions: To date, TRU-016 is a well-tolerated treatment with minimal infusional toxicity and the maximum tolerated dose (MTD) has not been reached. One partial response (PR) and a median reduction of 83% in peripheral lymphocytosis have been observed. Encouraging reduction in lymph node/spleen size and improvement in normal hematopoietic function in patients with high-risk genomic CLL have been observed at low doses of CD37. The protocol has been amended to explore higher saturating doses of CD37. Future single-agent and combination studies of TRU-016 in CLL are warranted.

Presentation 1744: Glycovariant CD37 Small Modular Immunopharmaceutical (Tru-ADhanCe(TM) SMIP) Promotes Enhanced Natural Killer Cell Mediated Cytotoxicity against Primary CLL Cells

Saturday, Dec. 5, 2009, 5:30 PM-7:30 PM
Hall E (Ernest N. Morial Convention Center)
Poster Board I-766

Conclusions: Results of this study suggest that Tru-ADhanCe(TM) technology promotes enhanced natural killer cell mediated cytotoxicity against primary CLL cells and the potential use of Tru-ADhanCe versions of TRU-016 with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) function as an alternate for TRU-016 in B cell malignancies, including CLL therapy.